## SARS-CoV-2 / COVID-19 Antibodies

Accreditation Status: UKAS Schedule of Accreditation

Date Scheme started: 2020

Clinical Applicability: Detection of antibodies to SARS-CoV-2 / COVID-19 confirming previous

infection

Analytes: Antibodies to SARS-CoV-2 as IgG, Total Ig (SER/059)

Units for Reporting: Qualitative and quantitative responses, method dependent

Samples Distributed: Liquid format. Normal and pathological human serum

Number of Distributions per year: 6

Number of Samples per Distribution: 2

Frequency of Distributions: Every month as outlined in the Distribution Schedule

**Schedule of Analysis:** Data entry is via the web for the submission of results. Data analysis is

commenced 14 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics

**Data Analysis:** Group Laboratory Trimmed Mean (GLTM) with truncation at 2SD, SD, and CV%.

Reports also show method and manufacturer specific statistics.

Individual laboratory performance is expressed in terms of MRBIS, SDBIS, and MRVIS. The Designated Value (DV) for calculation of VI is the Method Laboratory

Trimmed Mean (MLTM)

Chosen Coefficient of Variation for quantitative results is 20%

Performance Scoring: MI scoring and MRVIS

**Criteria of Performance:** Laboratory performance for the qualitative element of the Scheme is assessed over

a running analytical window of 12 Distributions (12 months)

Good OMIS = 0Adequate OMIS = 1 - 2Poor OMIS = > 2

Individual laboratory performance over a running analytical window of 12 Distributions (12 months) quantitation is expressed in terms of MRBIS, SDBIS and

MRVIS

 $\begin{array}{ccc} \text{Ideal} & \text{MRVIS} & <50 \\ \text{Good} & 50-100 \\ \text{Adequate} & 101-200 \end{array}$ 

Poor >200 or SDBIS >200

**Persistent Poor Performance:** Defined as being in the Poor Performance category for two or more

successive distributions